Organigram Global (OGI) to Release Quarterly Earnings on Monday

Posted by on May 4th, 2026

Organigram Global (NASDAQ:OGI – Get Free Report) is expected to issue its Q2 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $50.7080 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 8:00 AM ET.

Organigram Global (NASDAQ:OGI – Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The company had revenue of $46.27 million during the quarter, compared to analyst estimates of $73.38 million. Organigram Global had a net margin of 6.03% and a negative return on equity of 15.41%. On average, analysts expect Organigram Global to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organigram Global Stock Down 0.4%

OGI stock traded down $0.01 during trading hours on Monday, hitting $1.42. The company’s stock had a trading volume of 62,837 shares, compared to its average volume of 726,699. The company has a market capitalization of $199.19 million, a PE ratio of 10.18 and a beta of 1.50. Organigram Global has a 12 month low of $1.09 and a 12 month high of $2.24. The stock has a 50 day moving average price of $1.41 and a two-hundred day moving average price of $1.56.

Hedge Funds Weigh In On Organigram Global

Institutional investors have recently added to or reduced their stakes in the company. Walleye Capital LLC acquired a new position in Organigram Global during the fourth quarter worth $25,000. StoneX Group Inc. acquired a new position in Organigram Global during the fourth quarter worth $30,000. HRT Financial LP acquired a new position in Organigram Global during the fourth quarter worth $52,000. Bank of America Corp DE increased its holdings in Organigram Global by 1,678.1% during the third quarter. Bank of America Corp DE now owns 37,357 shares of the company’s stock worth $76,000 after buying an additional 35,256 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Organigram Global in the fourth quarter valued at $188,000. 34.63% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. ATB Cormark Capital Markets downgraded shares of Organigram Global from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, February 11th. Canaccord Genuity Group started coverage on shares of Organigram Global in a research report on Tuesday, January 27th. They set a “buy” rating for the company. Finally, Wall Street Zen upgraded shares of Organigram Global from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Read Our Latest Research Report on OGI

About Organigram Global

(Get Free Report)

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.

Featured Stories

Earnings History for Organigram Global (NASDAQ:OGI)

Receive News & Ratings for Organigram Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram Global and related companies with MarketBeat.com's FREE daily email newsletter.